#ESMO26: Dostarlimab monotherapy produced high rates of clinical complete response in patients with mismatch repair deficient (#dMMR)/microsatellite-high (#MSI-H) locally advanced #RectalCancer in the phase II AZUR-1 trial
🔗 https://ow.ly/iizM5100ny7
#InsightsbyESMO #immunotherapy
🔗 https://ow.ly/iizM5100ny7
#InsightsbyESMO #immunotherapy
October 27, 2026 at 11:00 AM
#ESMO26: Dostarlimab monotherapy produced high rates of clinical complete response in patients with mismatch repair deficient (#dMMR)/microsatellite-high (#MSI-H) locally advanced #RectalCancer in the phase II AZUR-1 trial
🔗 https://ow.ly/iizM5100ny7
#InsightsbyESMO #immunotherapy
🔗 https://ow.ly/iizM5100ny7
#InsightsbyESMO #immunotherapy
AZUR-1: Dostarlimab alone achieved 68% sustained complete response at 12 months in dMMR/MSI-H locally advanced rectal cancer. Could IO spare patients chemo, radiotherapy & surgery? Watch here👉https://ow.ly/hBAx5100VhW @MeredithPelster @SCRIOncology #ESMO26 #RectalCancer
Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer - ecancer
Dr Meredith Pelster speaks to ecancer about the first results from the global registrational AZUR-1 trial, which evaluated dostarlimab monotherapy in patients w
ow.ly
October 26, 2026 at 11:59 AM
AZUR-1: Dostarlimab alone achieved 68% sustained complete response at 12 months in dMMR/MSI-H locally advanced rectal cancer. Could IO spare patients chemo, radiotherapy & surgery? Watch here👉https://ow.ly/hBAx5100VhW @MeredithPelster @SCRIOncology #ESMO26 #RectalCancer
FDA grants accelerated approval to Jemperli for rectal cancer — immunotherapy alone, no chemo, radiation, or surgery for responders www.humolyte.com/blog/jemperl... #RectalCancer #Immunotherapy #CancerNews
October 22, 2026 at 9:43 PM
FDA grants accelerated approval to Jemperli for rectal cancer — immunotherapy alone, no chemo, radiation, or surgery for responders www.humolyte.com/blog/jemperl... #RectalCancer #Immunotherapy #CancerNews
Organ Preservation With Total Neoadjuvant Therapy (OPTNT) for Early Low #RectalCancer: Short-Term Outcomes of a Nonrandomized Phase 2 Clinical Trial. www.redjournal.org/article/S036...
Organ Preservation With Total Neoadjuvant Therapy (OPTNT) for Early Low Rectal Cancer: Short-Term Outcomes of a Nonrandomized Phase 2 Clinical Trial
Total mesorectal excision (TME) is standard for low rectal cancer (≤5cm from anal
verge) but causes permanent stomas, functional impairments and surgical risks. Local
excision (LE) suits early tumors ...
www.redjournal.org
October 23, 2026 at 9:42 AM
Organ Preservation With Total Neoadjuvant Therapy (OPTNT) for Early Low #RectalCancer: Short-Term Outcomes of a Nonrandomized Phase 2 Clinical Trial. www.redjournal.org/article/S036...
It’s no longer an old person’s disease.
#ItsColonoscopyTime #CancerSongs #RectalCancer #CancerAdvocacy #Survivorship
#ItsColonoscopyTime #CancerSongs #RectalCancer #CancerAdvocacy #Survivorship
October 20, 2026 at 10:00 PM
It’s no longer an old person’s disease.
#ItsColonoscopyTime #CancerSongs #RectalCancer #CancerAdvocacy #Survivorship
#ItsColonoscopyTime #CancerSongs #RectalCancer #CancerAdvocacy #Survivorship
A major advance for rectal cancer. The FDA has approved Jemperli immunotherapy for certain stage II/III tumours, potentially allowing patients to avoid chemotherapy, radiation and surgery.
www.fda.gov/drugs/resour...
#RectalCancer #TCSC
www.fda.gov/drugs/resour...
#RectalCancer #TCSC
FDA grants accelerated approval to dostarlimab for locally advanced re
Oncology Burst: FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer
www.fda.gov
October 20, 2026 at 9:05 AM
A major advance for rectal cancer. The FDA has approved Jemperli immunotherapy for certain stage II/III tumours, potentially allowing patients to avoid chemotherapy, radiation and surgery.
www.fda.gov/drugs/resour...
#RectalCancer #TCSC
www.fda.gov/drugs/resour...
#RectalCancer #TCSC
🚨 FDA NEWS |
AZUR 1 Update in #RectalCancer
FDA grants accelerated approval to dostarlimab (Jemperli) for previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer.First immunotherapy in this setting — may allow some patients to avoid chemo, radiation, and surgery.
AZUR 1 Update in #RectalCancer
FDA grants accelerated approval to dostarlimab (Jemperli) for previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer.First immunotherapy in this setting — may allow some patients to avoid chemo, radiation, and surgery.
October 19, 2026 at 5:44 PM
🚨 FDA NEWS |
AZUR 1 Update in #RectalCancer
FDA grants accelerated approval to dostarlimab (Jemperli) for previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer.First immunotherapy in this setting — may allow some patients to avoid chemo, radiation, and surgery.
AZUR 1 Update in #RectalCancer
FDA grants accelerated approval to dostarlimab (Jemperli) for previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer.First immunotherapy in this setting — may allow some patients to avoid chemo, radiation, and surgery.
Novel #radiotherapy may save increasingly many #rectalcancer patients from #surgery and #stoma. 🇫🇮 Finland is at the forefront of implementing this novel treatment.
New radiotherapy approach to spare rectal cancer patients surgery and stoma
Tampere University Hospital (Tays) has begun to offer a new radiotherapy to treat rectal cancer in which an intensive dose of radiation is targeted to the tumour surface.
healthcare-in-europe.com
October 19, 2026 at 5:08 AM
Novel #radiotherapy may save increasingly many #rectalcancer patients from #surgery and #stoma. 🇫🇮 Finland is at the forefront of implementing this novel treatment.
Among patients undergoing open rectal resection for #RectalCancer, a powdered #ChondroitinSulfate adhesion barrier system reduced postoperative adhesion incidence, severity, and extent vs no additional procedure.
ja.ma/4s9PmbB
ja.ma/4s9PmbB
October 16, 2026 at 11:00 AM
Among patients undergoing open rectal resection for #RectalCancer, a powdered #ChondroitinSulfate adhesion barrier system reduced postoperative adhesion incidence, severity, and extent vs no additional procedure.
ja.ma/4s9PmbB
ja.ma/4s9PmbB
Interpretable prediction of lymphopenia following neo-adjuvant chemo-radiotherapy for #RectalCancer: An analysis of the XXXX trial. www.clinicaloncologyonline.net/article/S093...
Interpretable prediction of lymphopenia following neo-adjuvant chemo-radiotherapy for rectal cancer: An analysis of the XXXX trial
To develop a mechanistic model explaining the development of lymphopenia during neoadjuvant
chemoradiotherapy and investigate how changes in lymphocyte counts relate to survival
in patients with local...
www.clinicaloncologyonline.net
October 16, 2026 at 8:40 AM
Interpretable prediction of lymphopenia following neo-adjuvant chemo-radiotherapy for #RectalCancer: An analysis of the XXXX trial. www.clinicaloncologyonline.net/article/S093...
📊 Among patients with #RectalCancer treated with total neoadjuvant treatment, watch-and-wait was associated with better long-term bowel function, social and physical functioning, role functioning, and global health status vs total mesorectal excision.
ja.ma/3TBUPLK
ja.ma/3TBUPLK
October 15, 2026 at 6:15 PM
📊 Among patients with #RectalCancer treated with total neoadjuvant treatment, watch-and-wait was associated with better long-term bowel function, social and physical functioning, role functioning, and global health status vs total mesorectal excision.
ja.ma/3TBUPLK
ja.ma/3TBUPLK
A blood test could help personalise rectal cancer surgery. In a Phase 2 study, detectable tumour DNA fell from 45.8% before chemotherapy to 8.7% afterwards, potentially helping doctors identify patients who need more extensive surgery.
www.curetoday.com/view/rectal-...
#RectalCancer #Cancer #TCSC
www.curetoday.com/view/rectal-...
#RectalCancer #Cancer #TCSC
Rectal Cancer Tumor DNA Fell From 45.8% to 8.7% After Chemotherapy | CURE
In the phase 2 CO.28 trial, all 4 patients with tumor DNA in their blood after chemotherapy were recommended surgery, versus 38.1% of those without it.
www.curetoday.com
October 12, 2026 at 8:06 AM
A blood test could help personalise rectal cancer surgery. In a Phase 2 study, detectable tumour DNA fell from 45.8% before chemotherapy to 8.7% afterwards, potentially helping doctors identify patients who need more extensive surgery.
www.curetoday.com/view/rectal-...
#RectalCancer #Cancer #TCSC
www.curetoday.com/view/rectal-...
#RectalCancer #Cancer #TCSC
Next up in our @sinclaircri.bsky.social seminar series is Dr. Christopher Nicol, Director of our Cancer Biology & Genetics division. Join us at 4:00 on Oct. 22nd - everyone is welcome!
Qs? Send us an email: scri@queensu.ca
#CancerResearch #RectalCancer #CancerBiology
Qs? Send us an email: scri@queensu.ca
#CancerResearch #RectalCancer #CancerBiology
September 29, 2026 at 7:46 PM
Next up in our @sinclaircri.bsky.social seminar series is Dr. Christopher Nicol, Director of our Cancer Biology & Genetics division. Join us at 4:00 on Oct. 22nd - everyone is welcome!
Qs? Send us an email: scri@queensu.ca
#CancerResearch #RectalCancer #CancerBiology
Qs? Send us an email: scri@queensu.ca
#CancerResearch #RectalCancer #CancerBiology
The TRAINER phase II study evaluates #Biomarker-driven total #Neoadjuvant therapy with bevacizumab or cetuximab for high-risk #RectalCancer, reporting complete responses and high sphincter preservation.
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
September 26, 2026 at 6:30 AM
The TRAINER phase II study evaluates #Biomarker-driven total #Neoadjuvant therapy with bevacizumab or cetuximab for high-risk #RectalCancer, reporting complete responses and high sphincter preservation.
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
Transanal tube for the prevention of anastomotic leakage in #RectalCancer surgery. www.cochranelibrary.com/cdsr/doi/10....
www.cochranelibrary.com
September 25, 2026 at 10:14 AM
Transanal tube for the prevention of anastomotic leakage in #RectalCancer surgery. www.cochranelibrary.com/cdsr/doi/10....
Tumor Immune Microenvironment and Response to Preoperative Chemoradiotherapy in Locally Advanced #RectalCancer: Results From the STAR-01 Study Cohort. ascopubs.org/doi/10.1200/...
Tumor Immune Microenvironment and Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer: Results From the STAR-01 Study Cohort | JCO Precision Oncology
PurposePreoperative chemoradiotherapy (CRT) can reshape the composition of the tumor immune
microenvironment (TIME) in locally advanced rectal cancer (LARC), augmenting T-cell
density and activation. ...
ascopubs.org
September 25, 2026 at 9:25 AM
Tumor Immune Microenvironment and Response to Preoperative Chemoradiotherapy in Locally Advanced #RectalCancer: Results From the STAR-01 Study Cohort. ascopubs.org/doi/10.1200/...
Tampere hospital begins Finland’s first targeted rectal cancer treatment #cancertreatment #rectalcancer #Tampere
Tampere hospital begins Finland’s first targeted rectal cancer treatment
Tampere University Hospital has become the first hospital in Finland to use a new radiation treatment for rectal cancer, Yle reports. The treatment delivers a high radiation dose through the rectum directly next to the tumour. The aim is to destroy the tumour while allowing more patients to avoid…
www.dailynorthern.com
September 11, 2026 at 1:45 PM
Tampere hospital begins Finland’s first targeted rectal cancer treatment #cancertreatment #rectalcancer #Tampere
Among patients undergoing open rectal resection for #RectalCancer, a powdered #ChondroitinSulfate adhesion barrier system reduced postoperative adhesion incidence, severity, and extent vs no additional procedure.
ja.ma/46eV3Lk
ja.ma/46eV3Lk
September 7, 2026 at 12:00 PM
Among patients undergoing open rectal resection for #RectalCancer, a powdered #ChondroitinSulfate adhesion barrier system reduced postoperative adhesion incidence, severity, and extent vs no additional procedure.
ja.ma/46eV3Lk
ja.ma/46eV3Lk
#Surgical treatment of #rectalcancer often means complete removal of the rectum. Now, newly published results from a trial co-led by 🇳🇱 @radboudumc.bsky.social suggest a different approach that lets patients keep their rectum – along with significant #quality-of-life benefits. #Oncology
Rectal cancer treatment spares surgery for most patients
Combined chemoradiotherapy allows four out of five patients with early- and intermediate-stage rectal cancer to keep their rectum.
healthcare-in-europe.com
August 31, 2026 at 6:35 AM
#Surgical treatment of #rectalcancer often means complete removal of the rectum. Now, newly published results from a trial co-led by 🇳🇱 @radboudumc.bsky.social suggest a different approach that lets patients keep their rectum – along with significant #quality-of-life benefits. #Oncology
Chemoradiotherapy vs short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage #RectalCancer (STAR-TREC): 12-month results of international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial. www.thelancet.com/journals/lan...
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multic...
These early results support a response-adapted organ-preservation approach, with LCCRT
appearing more effective than SCRT at 12 months. Organ-preservation might also reduce
treatment-related toxicity ...
www.thelancet.com
August 28, 2026 at 8:43 AM
Chemoradiotherapy vs short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage #RectalCancer (STAR-TREC): 12-month results of international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial. www.thelancet.com/journals/lan...
Have you been diagnosed with locally advanced #RectalCancer?
Share your experience as part of an anticipated upcoming Canadian funding review of dostarlimab (JEMPERLI®).
📞+1 833-792-2726 ext. 1001
📨cassandra.m@ccran.org
Share your experience as part of an anticipated upcoming Canadian funding review of dostarlimab (JEMPERLI®).
📞+1 833-792-2726 ext. 1001
📨cassandra.m@ccran.org
August 26, 2026 at 1:51 PM
Have you been diagnosed with locally advanced #RectalCancer?
Share your experience as part of an anticipated upcoming Canadian funding review of dostarlimab (JEMPERLI®).
📞+1 833-792-2726 ext. 1001
📨cassandra.m@ccran.org
Share your experience as part of an anticipated upcoming Canadian funding review of dostarlimab (JEMPERLI®).
📞+1 833-792-2726 ext. 1001
📨cassandra.m@ccran.org
FDA accepted GSK's Jemperli (dostarlimab) for priority review in untreated dMMR/MSI-H rectal cancer (24 Aug). AZUR-1 data; not approved for this use yet. PDUFA Feb 2027. Ask oncology. corterve.com/trials?condition=rectal+cancer #RectalCancer #ClinicalTrials
August 25, 2026 at 9:10 PM
FDA accepted GSK's Jemperli (dostarlimab) for priority review in untreated dMMR/MSI-H rectal cancer (24 Aug). AZUR-1 data; not approved for this use yet. PDUFA Feb 2027. Ask oncology. corterve.com/trials?condition=rectal+cancer #RectalCancer #ClinicalTrials
🆕Our Sept issue is now live!
📊Articles: #hepatocellularcarcinoma #NSCLC #rectalcancer #breastcancer #prostatecancer
📉Featuring trials: EMERALD-3, HARMONi, ALINA, STAR-TREC, & GETUG AFU 18
🎨Cover: breast cancer, TILs, and AI
🖱️Read here: www.thelancet.com/issue/S1470-...
📊Articles: #hepatocellularcarcinoma #NSCLC #rectalcancer #breastcancer #prostatecancer
📉Featuring trials: EMERALD-3, HARMONi, ALINA, STAR-TREC, & GETUG AFU 18
🎨Cover: breast cancer, TILs, and AI
🖱️Read here: www.thelancet.com/issue/S1470-...
August 25, 2026 at 10:06 AM
🆕Our Sept issue is now live!
📊Articles: #hepatocellularcarcinoma #NSCLC #rectalcancer #breastcancer #prostatecancer
📉Featuring trials: EMERALD-3, HARMONi, ALINA, STAR-TREC, & GETUG AFU 18
🎨Cover: breast cancer, TILs, and AI
🖱️Read here: www.thelancet.com/issue/S1470-...
📊Articles: #hepatocellularcarcinoma #NSCLC #rectalcancer #breastcancer #prostatecancer
📉Featuring trials: EMERALD-3, HARMONi, ALINA, STAR-TREC, & GETUG AFU 18
🎨Cover: breast cancer, TILs, and AI
🖱️Read here: www.thelancet.com/issue/S1470-...
In minimally invasive #rectalCancer surgery, low ligation of the inferior mesenteric artery did not significantly reduce symptomatic anastomotic leakage compared to high ligation. ja.ma/4cJZt0c
IMA Ligation Level and Anastomotic Leak in Low Anterior Resection
This randomized clinical trial compares outcomes for patients undergoing minimally invasive anterior resection to determine whether low ligation of the inferior mesenteric artery (IMA) reduces the rate of anastomotic leakage compared with high ligation.
ja.ma
August 22, 2026 at 12:00 PM
In minimally invasive #rectalCancer surgery, low ligation of the inferior mesenteric artery did not significantly reduce symptomatic anastomotic leakage compared to high ligation. ja.ma/4cJZt0c